1
|
Wintermark M, Gupta V, Hess C, Lee R, Maldjian J, Mukherjee S, Mukherji S, Seidenwurm D, Kennedy T. Realistic Productivity in Academic Neuroradiology: A National Survey of Neuroradiology Division Chiefs. AJNR Am J Neuroradiol 2023:ajnr.A7912. [PMID: 37348969 PMCID: PMC10337619 DOI: 10.3174/ajnr.a7912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Accepted: 05/08/2023] [Indexed: 06/24/2023]
|
2
|
Yan M, Sigurdson S, Greifer N, Kennedy T, Toh T, Jr PL, Weiss J, Hueniken K, Yeung C, Sugumar V, Sun A, Bezjak A, Cho J, Raman S, Hope A, Giuliani M, Stuart E, Owen T, Ashworth A, Robinson A, Liu G, Moraes F, Lok B. A Comparison of Hypofractionated and Twice Daily Thoracic Irradiation in Limited-Stage Small Cell Lung Cancer: An Overlap Weighted Analysis. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
3
|
Lee J, Schroth RJ, Sturym M, DeMaré D, Rosteski M, Batson K, Chartrand F, Bertone MF, Kennedy T, Hai-Santiago K. Oral Health Status and Oral Health-Related Quality of Life of First Nations and Metis Children. JDR Clin Trans Res 2021; 7:435-445. [PMID: 34672839 PMCID: PMC9490442 DOI: 10.1177/23800844211037992] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Objectives: To assess the oral health status and oral health–related quality of life (OHRQoL) of young First Nations and Metis children. Methods: This cross-sectional study assessed the oral health status of Indigenous children <72 mo of age while their parents/caregivers completed a questionnaire, including the Early Childhood Oral Health Impact Scale (ECOHIS), to assess OHRQoL. Analysis included descriptive statistics, bivariate analyses, and multiple regression. A P value ≤0.05 was considered significant. Results: Overall, 146 children were recruited with a mean age of 40.1 ± 21.2 (SD) months, and 49% were male. Among First Nations children, 65.4% had early childhood caries (ECC) as compared with 45.2% among Metis children (P = 0.025). However, there was no statistically significant difference in the prevalence of severe ECC (S-ECC) between First Nations and Metis children (60.6% v. 42.9%, P = 0.051). The mean decayed, missing, and filled primary teeth (dmft) score was 4.9 ± 5.3 (range 0–20), and the mean decayed, missing, and filled surfaces (dmfs) score was 14.5 ± 20.4 (range 0–80). The total mean ECOHIS score was 4.4 ± 5.9 (range 0–25), while the mean Child Impact Section and Family Impact Section scores were 2.6 ± 4.0 (range 0–10) and 1.8 ± 2.8 (range 0–8), respectively. Multiple linear regression showed S-ECC was associated with total mean ECOHIS scores (P = 0.02). Higher total mean ECOHIS scores (which indicates poorer OHRQoL) were observed in children with ECC compared with caries-free children (5.8 v. 2.4, P = 0.0001). Conclusion: Oral health disparities such as ECC and reduced OHRQoL exist among many First Nations and Metis children in Manitoba. This is the first Canadian study exploring the OHRQoL of Indigenous children in addition to their oral health status. Knowledge Transfer Statement: This study is the first to report on the oral health–related quality of life and its relationship to early childhood caries (ECC) among young Canadian First Nations and Metis children. Metis children are just as likely to suffer from severe ECC than First Nations children. The findings of this study have informed community-based and community-developed oral health promotion and ECC prevention activities.
Collapse
Affiliation(s)
- J Lee
- Department of Preventive Dental Science, Dr. Gerald Niznick College of Dentistry, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.,Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada
| | - R J Schroth
- Department of Preventive Dental Science, Dr. Gerald Niznick College of Dentistry, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.,Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada.,Department of Pediatrics and Child Health, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada
| | - M Sturym
- Department of Preventive Dental Science, Dr. Gerald Niznick College of Dentistry, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.,Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada
| | - D DeMaré
- Department of Preventive Dental Science, Dr. Gerald Niznick College of Dentistry, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.,Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada
| | - M Rosteski
- Manitoba Metis Federation, Winnipeg, MB, Canada
| | - K Batson
- Pine Creek First Nation, Camperville, MB, Canada
| | - F Chartrand
- Manitoba Metis Federation, Winnipeg, MB, Canada
| | - M F Bertone
- School of Dental Hygiene, Dr. Gerald Niznick College of Dentistry, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada
| | - T Kennedy
- Department of Preventive Dental Science, Dr. Gerald Niznick College of Dentistry, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada
| | - K Hai-Santiago
- Manitoba Health and Seniors Care, Government of Manitoba, Winnipeg, MB, Canada
| | -
- Healthy Smile Happy Child, Winnipeg, MB, Canada
| | -
- Pine Creek First Nation, Camperville, MB, Canada
| | -
- Manitoba Metis Federation, Winnipeg, MB, Canada
| |
Collapse
|
4
|
Merfeld E, Burr A, Kimple R, Witek M, Kennedy T, Avey G, Harari P. Diminishing Toxicity Profiles in Oropharynx Cancer. Can We Safely Spare Nodal Levels IB and V in the Majority of Patients? Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Golombek M, Williams N, Warner NH, Parker T, Williams MG, Daubar I, Calef F, Grant J, Bailey P, Abarca H, Deen R, Ruoff N, Maki J, McEwen A, Baugh N, Block K, Tamppari L, Call J, Ladewig J, Stoltz A, Weems WA, Mora‐Sotomayor L, Torres J, Johnson M, Kennedy T, Sklyanskiy E. Location and Setting of the Mars InSight Lander, Instruments, and Landing Site. Earth Space Sci 2020; 7:e2020EA001248. [PMID: 33134434 PMCID: PMC7583488 DOI: 10.1029/2020ea001248] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Revised: 09/09/2020] [Accepted: 09/12/2020] [Indexed: 06/11/2023]
Abstract
Knowing precisely where a spacecraft lands on Mars is important for understanding the regional and local context, setting, and the offset between the inertial and cartographic frames. For the InSight spacecraft, the payload of geophysical and environmental sensors also particularly benefits from knowing exactly where the instruments are located. A ~30 cm/pixel image acquired from orbit after landing clearly resolves the lander and the large circular solar panels. This image was carefully georeferenced to a hierarchically generated and coregistered set of decreasing resolution orthoimages and digital elevation models to the established positive east, planetocentric coordinate system. The lander is located at 4.502384°N, 135.623447°E at an elevation of -2,613.426 m with respect to the geoid in Elysium Planitia. Instrument locations (and the magnetometer orientation) are derived by transforming from Instrument Deployment Arm, spacecraft mechanical, and site frames into the cartographic frame. A viewshed created from 1.5 m above the lander and the high-resolution orbital digital elevation model shows the lander is on a shallow regional slope down to the east that reveals crater rims on the east horizon ~400 m and 2.4 km away. A slope up to the north limits the horizon to about 50 m away where three rocks and an eolian bedform are visible on the rim of a degraded crater rim. Azimuths to rocks and craters identified in both surface panoramas and high-resolution orbital images reveal that north in the site frame and the cartographic frame are the same (within 1°).
Collapse
Affiliation(s)
- M. Golombek
- Jet Propulsion LaboratoryCalifornia Institute of TechnologyPasadenaCAUSA
| | - N. Williams
- Jet Propulsion LaboratoryCalifornia Institute of TechnologyPasadenaCAUSA
| | - N. H. Warner
- Department of Geological SciencesSUNY GeneseoGeneseoNYUSA
| | - T. Parker
- Jet Propulsion LaboratoryCalifornia Institute of TechnologyPasadenaCAUSA
| | - M. G. Williams
- Jet Propulsion LaboratoryCalifornia Institute of TechnologyPasadenaCAUSA
| | - I. Daubar
- Jet Propulsion LaboratoryCalifornia Institute of TechnologyPasadenaCAUSA
- Department of Earth, Environmental, and Planetary SciencesBrown UniversityProvidenceRIUSA
| | - F. Calef
- Jet Propulsion LaboratoryCalifornia Institute of TechnologyPasadenaCAUSA
| | - J. Grant
- Smithsonian Institution, National Air and Space MuseumWashingtonDCUSA
| | - P. Bailey
- Jet Propulsion LaboratoryCalifornia Institute of TechnologyPasadenaCAUSA
| | - H. Abarca
- Jet Propulsion LaboratoryCalifornia Institute of TechnologyPasadenaCAUSA
| | - R. Deen
- Jet Propulsion LaboratoryCalifornia Institute of TechnologyPasadenaCAUSA
| | - N. Ruoff
- Jet Propulsion LaboratoryCalifornia Institute of TechnologyPasadenaCAUSA
| | - J. Maki
- Jet Propulsion LaboratoryCalifornia Institute of TechnologyPasadenaCAUSA
| | - A. McEwen
- Lunar and Planetary LaboratoryUniversity of ArizonaTucsonAZUSA
| | - N. Baugh
- Lunar and Planetary LaboratoryUniversity of ArizonaTucsonAZUSA
| | - K. Block
- Lunar and Planetary LaboratoryUniversity of ArizonaTucsonAZUSA
| | - L. Tamppari
- Jet Propulsion LaboratoryCalifornia Institute of TechnologyPasadenaCAUSA
| | - J. Call
- Jet Propulsion LaboratoryCalifornia Institute of TechnologyPasadenaCAUSA
| | | | | | | | - L. Mora‐Sotomayor
- Centro de Astrobiología (CSIC/INTA)Instituto Nacional de Técnica AeroespacialMadridSpain
| | - J. Torres
- Centro de Astrobiología (CSIC/INTA)Instituto Nacional de Técnica AeroespacialMadridSpain
| | | | | | - E. Sklyanskiy
- Jet Propulsion LaboratoryCalifornia Institute of TechnologyPasadenaCAUSA
| |
Collapse
|
6
|
Walsh KS, del Castillo A, Kennedy T, Karim AI, Semerjian C. A Review of Psychological, Social, and Behavioral Functions in the RASopathies. J Pediatr Neuropsychol 2020. [DOI: 10.1007/s40817-020-00088-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
7
|
Roy UB, Elkins I, Feldman J, Figueras A, Kennedy T. OA03.06 Impact of an EGFR-Lung Cancer Diagnosis on Quality of Life of Patients: Learnings from Project Priority. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Roy UB, Elkins I, Figueras A, Kennedy T. MA16.01 Project PRIORITY: A Patient-Founded and Patient-Driven Research Partnership on Real-World Data on EGFR-Positive Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
9
|
Sun F, Kennedy T. IMPROVEMENT OF PRACTICE OF ADULT PROTECTIVE SERVICES IN ARIZONA: IN-TAKE AND INVESTIGATION PROCESS REVIEW. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- F Sun
- School of Social Work, Michigan State University, East Lansing, Michigan, United States
| | - T Kennedy
- Arizona State Univeristy, Phoenix, AZ, USA
| |
Collapse
|
10
|
Kennedy T, Sellar PW, Vaideanu-Collins D, Ng J. Two case reports of zoledronic acid-induced uveitis. Age Ageing 2018; 47:754-755. [PMID: 29718071 DOI: 10.1093/ageing/afy070] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Accepted: 04/12/2018] [Indexed: 11/14/2022] Open
Abstract
Zoledronic acid (zoledronate) is a bisphosphonate used predominantly as a second-line treatment for post-menopausal osteoporosis. Its administration is associated with an acute phase reaction. Here, we present two cases of anterior uveitis following initial administration of zoledronate. In the first case, an 80-year-old lady presented with right eye pain and decreased visual acuity 24-hours post-infusion. Uveitis was diagnosed and sub-conjunctival injection of corticosteroids was required. In the second case, a 78-year-old lady presented with right eye pain, vomiting and decreased acuity 24-hours after infusion. She was treated with topical steroids and required cataract surgery to normalise visual acuity. Patients prescribed zoledronate should be warned of the risk of ocular side effects and asked to report promptly for treatment if they develop a red, painful eye or blurred vision.
Collapse
Affiliation(s)
| | | | | | - J Ng
- James Cook University Hospital
| |
Collapse
|
11
|
Valsamis EM, Sadler J, Kennedy T, Thornhill C, Carey C, Ricketts D. Anaesthesia: what a surgeon needs to know. Br J Hosp Med (Lond) 2018; 79:270-278. [PMID: 29727235 DOI: 10.12968/hmed.2018.79.5.270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Surgeons and anaesthetists work closely together, sometimes in challenging circumstances. To help surgeons cooperate with anaesthetists to deliver high quality care for patients, a working knowledge of modern anaesthetic practice is useful. The specialty of anaesthetics is developing rapidly, and periodic updating of this knowledge is likely to be required. This article provides an update of anaesthetic practice for surgeons, covering the varied roles of anaesthetists, preoperative assessment, management on the day of surgery (induction, maintenance and reversal of anaesthetic), general anaesthesia, the role of regional blocks and sedation. It also discusses safety issues, the management of frail patients and future challenges.
Collapse
Affiliation(s)
- E M Valsamis
- Core Surgical Trainee, Department of Trauma and Orthopaedics, Brighton and Sussex University Hospitals NHS Trust, Brighton BN2 5BE
| | - J Sadler
- Clinical Fellow in Anaesthesia, Department of Anaesthesia, Brighton and Sussex University Hospitals NHS Trust, Brighton
| | - T Kennedy
- Anaesthetic Trainee, Department of Anaesthesia, Brighton and Sussex University Hospitals NHS Trust, Brighton
| | - C Thornhill
- Medical Student, Brighton and Sussex University Hospitals NHS Trust, Brighton
| | - C Carey
- Consultant in Anaesthetics, Department of Anaesthesia, Brighton and Sussex University Hospitals NHS Trust, Brighton
| | - D Ricketts
- Consultant Orthopaedic Surgeon, Department of Trauma and Orthopaedics, Brighton and Sussex University Hospitals NHS Trust, Brighton
| |
Collapse
|
12
|
Wynne G, Vuorinen A, Emer E, Conole D, Chatzopoulou M, Davies S, Russell A, Guiraud S, Squire S, Berg A, Edwards B, Hemming S, Kennedy T, Moir L, Davies K, Harriman S, Tinsley J, Wilson F. Discovery of small molecule utrophin modulators for the therapy of Duchenne muscular dystrophy. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
13
|
Musunuru H, Yadav P, Ko H, Kennedy T, Harari P, Witek M. Can Elective Neck Radiation Treatment Volumes be Safely Reduced to Diminish Toxicity Profiles for Oropharynx Cancer Patients? Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
14
|
Affiliation(s)
- T. Kennedy
- School of Social Work, Arizona State University, Phoenix, Arizona,
| | | | - R. Mark
- Dublin City University, Dublin, Ireland,
- University of Strathclyde, Glasgow, Scotland, United Kingdom
| |
Collapse
|
15
|
Guiraud S, Chen H, Kennedy T, Squire S, Edwards B, Burns D, Shah N, Babbs A, Davies S, Wynne G, Russell A, Elsey D, Wilson F, Tinsley J, Davies K. Utrophin modulators significantly improve the muscular dystrophy in the mdx diaphragm. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
16
|
França K, Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Wollina U, Tirant M, Bayer P, Coburn M, Anderson P, Donnelly B, Kennedy T, Gaibor J, Arora M, Clews L, Novotny F, Roccia MG, Maximov GK, Lotti T. Investigation of the efficacy and tolerability of Dr Michaels® (also branded as Eczitinex® and Itchinex Eczitinex®) topical products in the treatment of atopic dermatitis in children. J BIOL REG HOMEOS AG 2016; 30:55-63. [PMID: 27498659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Atopic eczema is a chronic relapsing inflammatory skin disorder, characterized clinically by intensely pruritic eczematous skin lesions and a defective epidermal barrier. It affects more than 15% of children and up to 10%of adults, which makes the disease a social health problem still without a challenging treatment. The aim of this study was to evaluate the efficacy and tolerability of Dr Michaels® (Eczitinex®) topical product family in the treatment of atopic dermatitis in children. We studied a group of 30 patients (17 female, 13 male), aged 5 to 13 (mean age: 9), affected by atopic dermatitis since they were newborn. All patients had been unsuccessfully treated with conventional anti-inflammatory therapies and ceased treatment 2 weeks before commencing research. The patients were treated with Dr Michaels® (Eczitinex® and Itchinex®) product family including a moisturising bar, topical ointment and PSC 900 oral herbal formulation. The treatment was evaluated clinically and photographically at 0, 1, 2, 4, 6, 8, 10, 12, and 14 weeks. Twenty-eight patients showed a significant improvement of cutaneous rashes and pruritus on the first week of treatment, with a complete remission at 10-12 weeks. Only two patients, brother and sister respectively, showed a slow response to treatment and reported an increasing itching. Following 14 weeks of treatment with the Dr Michaels® (Eczitinex® and Itchinex®) product family, patients demonstrated complete resolution of their AD. All patients showed a marked improvement in their condition within 3 days of treatment with most of the lesions and symptoms totally resolved within 10 to 12 weeks of treatment with Dr Michaels® (Eczitinex® and Itchinex®) family of products. This clinical report highlights that the Dr Michaels® (Eczitinex® and Itchinex®) product family is a safe and effective treatment option for AD.
Collapse
Affiliation(s)
- K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; 7 Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Bayer
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Coburn
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Anderson
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - B Donnelly
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - T Kennedy
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - J Gaibor
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Arora
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - L Clews
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - F Novotny
- PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
17
|
Wollina U, Tirant M, Bayer P, Coburn M, Anderson P, Donnelly B, Kennedy T, Gaibor J, Arora M, Clews L, Walmsley S, Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. Successful treatment of mild to moderate acne vulgaris with Dr Michaels® (also branded as Zitinex®) topical products family: a clinical trial. J BIOL REG HOMEOS AG 2016; 30:49-54. [PMID: 27498658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Acne vulgaris is an epidemic inflammatory skin disease of multi-factorial origin, frequently seen in adolescents and often persisting or occurring through to adulthood. Acne vulgaris is a nearly universal skin disease afflicting 79-95% of the adolescent population in westernized societies and is a significant cause of psychological morbidity in affected patients. Despite the various treatment options available for acne, there is still a need for a safe and effective option. The aim of the study was to investigate the efficacy and tolerability of Dr Michaels® (Zitinex®) product family in the treatment of papulo-pustular acne. 25 patients (17 female/8 male), aged 15-22, with a mild to moderate papulo-pustular acne, localized on the face and on the trunk, were included in this study. None of the patients had used any other kind of treatment in the 3 months prior to commencing this study. All of the patients were treated with Dr Michaels® (Zitinex®) facial exfoliating cleanser, activator formula, a cream, PSC 200 and PSC 900 oral supplements. Application time of Dr Michaels® (Zitinex®) products was 12 weeks. The treatment was been evaluated clinically at 0, 4, 8 and 12 weeks. All of the patients showed an improvement in all parameters of their acne (comedones, papules, pustules, hyperpigmentation and scars). The acne lesions and erythema had mostly resolved. The hyperpigmentation and pitted scarring had significantly reduced also, with the skin appearing smoother. The treatment was well tolerated and no side effects have been described. Our study demonstrates that the Dr Michaels® (Zitinex®) facial exfoliating cleanser, activator formula, cream and oral supplements PSC 200 and PSC 900 are an effective therapeutic option for the treatment of moderately severe acne vulgaris. Moreover, it highlights the safety profile of the Dr Michaels® (Zitinex®) product family in a case of acne compared to traditional first-line treatments.
Collapse
Affiliation(s)
- U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Bayer
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Coburn
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Anderson
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - B Donnelly
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - T Kennedy
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - J Gaibor
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Arora
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - L Clews
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - S Walmsley
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma- Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - F Novotny
- PRO SANUM Ltd., Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
18
|
Hercogovấ J, Tirant M, Bayer P, Coburn M, Donnelly B, Kennedy T, Gaibor J, Arora M, Clews L, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Wollina U, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. Successful treatment of recalcitrant candidal intertrigo with Dr Michaels® (Fungatinex®) product family. J BIOL REG HOMEOS AG 2016; 30:89-93. [PMID: 27498664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Candidal intertrigo is an infection of the skin caused by Candida albicans that typically occurs in opposing cutaneous or muco-cutaneous surfaces. Because Candidiasis requires a damaged and moist environment for infection, it typically occurs in areas of friction such as the skin folds of the body. Candidal intertrigo is often difficult to treat and results are often unsatisfactory. In addition, there is a lack of evidence-based literature supporting prevention and treatments for candidal intertrigo. The aim of the study was to evaluate the efficacy of Dr Michaels® (also branded as Fungatinex®) products in the treatment of fungal intertrigo, in 20 women and 2 men with a mean age of 72. Five patients (3 female and 2 male) had type 2 diabetes and 16 (14 female and 2 male) were obese. The patients were treated with Dr Michaels® (Fungatinex®) moisturising bar, topical ointment (twice daily application) and oral herbal formulation, PSC 200 two tablets twice daily with food. After 2 weeks of treatment, the lesions had mostly resolved in all patients with only slight erythema evident. After six weeks of treatment using the moisturising bar, topical ointment and oral herbal formulations from the Dr Michaels® (Fungatinex®) product family, the lesions had totally resolved in 18 patients, while 4 patients had to continue the therapeutic protocol for another 2 weeks. Our results demonstrate that the Dr Michaels® (Fungatinex®) complementary product family is efficacious in the treatment of recalcitrant candidal intertrigo. Furthermore, this study highlights that the Dr Michaels® (Fungatinex®) product family is fast-acting and well tolerated with no serious adverse events reported. These data have important implications for resistant cases of candidal intertrigo where traditional therapies have failed.
Collapse
Affiliation(s)
- J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Bayer
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Coburn
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - B Donnelly
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - T Kennedy
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - J Gaibor
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Arora
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - L Clews
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, Guglielmo Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - F Novotny
- PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
19
|
Wieland A, Witek M, Wojcieszynski A, Kennedy T, Hartig G, Harari P. Long-Term Outcomes for Head and Neck Cancer Patients With N3 Neck Disease. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2015.12.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
Connor V, Tippet V, Kennedy T, Challoner B. P289 Isolated Mediastinal and/or Hilar Lymphadenopathy: what can EBUS-TBNA add?: Abstract P289 Table 1. Thorax 2015. [DOI: 10.1136/thoraxjnl-2015-207770.425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
21
|
Ahmed A, Rogers S, Bruce H, Kennedy T, Kirton J, O'Brien M, Frankland H, Mediana A, Moots R. THU0332 Development of a Rheumatology-Specific Patient Concerns Inventory (PCI) and its Use in the Rheumatology Outpatient Clinic Setting. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5947] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
22
|
Millen A, Coulston J, Brennan J, Kennedy T. The use of immunosuppressive agents in the management of recalcitrant lower limb ulcers. J Wound Care 2014; 23:388-92. [PMID: 25139596 DOI: 10.12968/jowc.2014.23.8.388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
OBJECTIVE Lower limb ulcers that are resistant to standard forms of treatment place a significant burden on both patients and health services. There is no widely agreed definition of a recalcitrant ulcer but failure to heal following 6-12 months of focused treatment would identify a small group of patients with highly resistant ulceration. We describe a series of patients with recalcitrant ulceration for which immunosuppressive agents have been used. METHODS This is a case series of 13 patients who underwent immunomodulation therapy for lower limb ulcers at a tertiary referral university hospital. Regimens of immunomodulation used mainly ciclosporin and/or cyclophosphamide, with concurrent antibiotic therapy. Case notes and computer systems were analysed by two reviewers. A patient was deemed to have a success if their ulcer fully healed while on immunomodulation therapy. RESULTS Over a period of eight years, from 2004-2012, 13 patients underwent immunomodulation therapy. Among these patients there were 18 ulcerated limbs. Ulcer healing occurred in 10 limbs out of 18 (55.6%) and full healing occurred in six patients (46.2%). Ulcers were present for a median of five years (range 2-40 years), with a median diameter of 7.5 cm (range 4-18 cm) before treatment. CONCLUSION Treatment of truly recalcitrant ulceration can be very frustrating for both the patient and physician, with poor success from more standard forms of treatment. We report experience with immunomodulation therapy that suggests there may be benefit from using this treatment in a subset of patients with this debilitating disease.
Collapse
Affiliation(s)
- A Millen
- Clinical Research Fellow, Royal Liverpool University Hospital; UK
| | | | | | | |
Collapse
|
23
|
Reinemeyer C, Prado J, Andersen U, Nielsen M, Schricker B, Kennedy T. Effects of daily pyrantel tartrate on strongylid population dynamics and performance parameters of young horses repeatedly infected with cyathostomins and Strongylus vulgaris. Vet Parasitol 2014; 204:229-37. [DOI: 10.1016/j.vetpar.2014.05.034] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2013] [Revised: 05/14/2014] [Accepted: 05/16/2014] [Indexed: 10/25/2022]
|
24
|
Abstract
Mass culling is a strategy used inthe management of infectious disease outbreaks. The risk of disease spread due to animal transportation often precludes the use of slaughterhouses for this purpose, though they have been used on occasion. Consequently, culling takes place in the less-than-standardised environment on the farm. Regardless of where the cull occurs, the methods chosen to handle and kill the animals must preserve their welfare. This paper attempts to apply the best welfare practices from the controlled environment of the slaughterhouse to the mass culling of ruminants, pigs and poultry. It investigates the key welfare challenges and identifies astute planning executed by competent personnel as a crucial success factor. The urgency; capacity; species, type and age of the animal; personnel; and availability of equipment determine the restraint and killing methods used. The use of good on-farm restraining facilities and mobile killing devices can reasonably be expected to maintain welfare standards for ruminants and poultry. The pig's anatomy, natural behaviour, wide age range and housing types present additional challenges. Objective monitoring throughout the operation is vital for implementing immediate corrective measures whilst also informing procedural reviews. The authors suggest a monitoring tool based on a system currently used in abattoirs, but its limitations must first be validated.
Collapse
|
25
|
Stevenson WS, Best OG, Przybylla A, Chen Q, Singh N, Koleth M, Pierce S, Kennedy T, Tong W, Kuang SQ, Garcia-Manero G. DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia. Leukemia 2014; 28:787-93. [PMID: 24045499 DOI: 10.1038/leu.2013.270] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2013] [Revised: 08/20/2013] [Accepted: 09/03/2013] [Indexed: 02/03/2023]
Abstract
Aberrant DNA promoter methylation with associated gene silencing is a common epigenetic abnormality in acute lymphoblastic leukaemia (ALL) and is associated with poor survival. We have identified a family of transmembrane tyrosine phosphatase proteins as targets of hypermethylation in ALL and high-grade B cell lymphoma and demonstrated that this abnormal methylation correlates with transcript expression. PTPRG was methylated in 63% of ALL samples, PTPRK in 47%, PTPRM in 64% and PTPRO in 54% of cases, with most ALL samples containing methylation at multiple phosphatase loci. PTPRK promoter methylation was associated with a decreased overall survival in the cohort. Restoration of PTPRK transcript levels in leukaemia cells, where phosphatase transcript was silenced, reduced cell proliferation, inhibited colony formation and increased sensitivity to cytotoxic chemotherapy. These biological changes were associated with a reduction in levels of phosphorylated Erk1/2, Akt, STAT3 and STAT5 suggesting functional phosphatase activity after transcript re-expression. Methylation of the phosphatase promoters was reversible with decitabine and a histone deacetylase inhibitor, suggesting that PTPRK-mediated cell signalling pathways may be targeted with epigenetic therapies in lymphoid malignancy.
Collapse
Affiliation(s)
- W S Stevenson
- 1] Department of Haematology, Royal North Shore Hospital, Pathology North, Sydney, Australia [2] Northern Blood Research Centre, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia
| | - O G Best
- Northern Blood Research Centre, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia
| | - A Przybylla
- Northern Blood Research Centre, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia
| | - Q Chen
- 1] Department of Haematology, Royal North Shore Hospital, Pathology North, Sydney, Australia [2] Northern Blood Research Centre, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia
| | - N Singh
- Department of Haematology, Royal North Shore Hospital, Pathology North, Sydney, Australia
| | - M Koleth
- Department of Haematology, Royal North Shore Hospital, Pathology North, Sydney, Australia
| | - S Pierce
- Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - T Kennedy
- Department of Haematology, Royal North Shore Hospital, Pathology North, Sydney, Australia
| | - W Tong
- Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - S-Q Kuang
- Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| | - G Garcia-Manero
- Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
26
|
Evans S, Thomas D, Grant S, Aubuchon-Endsley N, Kennedy T. Greater Developmental Change in Information Processing Speed in Breastfed Infants Associated with Maternal Intake. J Acad Nutr Diet 2013. [DOI: 10.1016/j.jand.2013.06.329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
27
|
Osiak M, Khunsin W, Armstrong E, Kennedy T, Torres CMS, Ryan KM, O'Dwyer C. Epitaxial growth of visible to infra-red transparent conducting In2O3 nanodot dispersions and reversible charge storage as a Li-ion battery anode. Nanotechnology 2013; 24:065401. [PMID: 23340017 DOI: 10.1088/0957-4484/24/6/065401] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Unique bimodal distributions of single crystal epitaxially grown In2O3 nanodots on silicon are shown to have excellent IR transparency greater than 87% at IR wavelengths up to 4 μm without sacrificing transparency in the visible region. These broadband antireflective nanodot dispersions are grown using a two-step metal deposition and oxidation by molecular beam epitaxy, and backscattered diffraction confirms a dominant (111) surface orientation. We detail the growth of a bimodal size distribution that facilitates good surface coverage (80%) while allowing a significant reduction in In2O3 refractive index. This unique dispersion offers excellent surface coverage and three-dimensional volumetric expansion compared to a thin film, and a step reduction in refractive index compared to bulk active materials or randomly porous composites, to more closely match the refractive index of an electrolyte, improving transparency. The (111) surface orientation of the nanodots, when fully ripened, allows minimum lattice mismatch strain between the In2O3 and the Si surface. This helps to circumvent potential interfacial weakening caused by volume contraction due to electrochemical reduction to lithium, or expansion during lithiation. Cycling under potentiodynamic conditions shows that the transparent anode of nanodots reversibly alloys lithium with good Coulombic efficiency, buffered by co-insertion into the silicon substrate. These properties could potentially lead to further development of similarly controlled dispersions of a range of other active materials to give transparent battery electrodes or materials capable of non-destructive in situ spectroscopic characterization during charging and discharging.
Collapse
Affiliation(s)
- M Osiak
- Department of Chemistry, University College Cork, Cork, Ireland
| | | | | | | | | | | | | |
Collapse
|
28
|
Reinemeyer C, Prado J, Schricker B, Kennedy T. Parasitologic, Physiologic, and Performance Parameters of Yearling Horses Receiving Daily Pyrantel Tartrate. J Equine Vet Sci 2012. [DOI: 10.1016/j.jevs.2012.08.089] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
29
|
Packer RJ, Rood BR, Onar-Thomas A, Goldman S, Fisher MJ, Smith C, Boyett J, Kun L, Nelson MB, Compton P, Macey P, Patel S, Jacob E, O'Neil S, Finlay J, Harper R, Legault G, Chhabra A, Allen JC, Si SJ, Flores N, Haley K, Malvar J, Fangusaro J, Dhall G, Sposto R, Davidson TB, Finlay JL, Krieger M, Finlay JL, Zhou T, Miller DC, Geyer JR, Pollack IF, Gajjar A, Cohen BH, Nellan A, Murray JC, Honeycutt J, Gomez A, Head H, Braly E, Puccetti DM, Patel N, Kennedy T, Bradley K, Howard S, Salamat S, Iskandar B, Slavc I, Peyrl A, Chocholous M, Kieran M, Azizi A, Czech T, Dieckmann K, Haberler C, Sadighi ZS, Ellezam B, Khatua S, Ater J, Biswas A, Kakkar A, Goyal S, Mallick S, Sarkar C, Sharma MC, Julka PK, Rath GK, Glass T, Cochrane DD, Rassekh SR, Goddard K, Hukin J, Deopujari CE, Khakoo Y, Hanmantgad S, Forester K, McDonald SA, De Braganca K, Yohay K, Wolff JE, Kwiecien R, Rutkowski S, Pietsch T, Faldum A, Kortmann RD, Kramm C, Fouladi M, Olson J, Stewart C, Kocak M, Onar-Thomas A, Wagner L, Packer R, Goldman S, Gururangan S, Blaney S, Pollack I, Smith C, Demuth T, Kun L, Boyett J, Gilbertson R, Powell MK, Klement GL, Roffidal T, Fonkem E, Wolff JE. CLIN-PEDIATRICS CLINICAL RESEARCH. Neuro Oncol 2012. [DOI: 10.1093/neuonc/nos234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Leonard A, Wolff J, Sengupta R, Marassa J, Piwnica-Worms D, Rubin J, Pollack I, Jakacki R, Butterfield L, Okada H, Fangusaro J, Warren KE, Mullins C, Jurgen P, Julia S, Friedrich CC, Keir S, Saling J, Roskoski M, Friedman H, Bigner D, Moertel C, Olin M, Dahlheimer T, Gustafson M, Sumstad D, McKenna D, Low W, Nascene D, Dietz A, Ohlfest J, Sturm D, Witt H, Hovestadt V, Quan DAK, Jones DTW, Konermann C, Pfaff E, Korshunov A, Rizhova M, Milde T, Witt O, Zapatka M, Collins VP, Kool M, Reifenberger G, Lichter P, Lindroth AM, Plass C, Jabado N, Pfister SM, Pizer B, Salehzadeh A, Brodbelt A, Mallucci C, Brassesco M, Pezuk J, Morales A, de Oliveira J, Roberto G, Umezawa K, Valera E, Rego E, Scrideli C, Tone L, Veringa SJE, Van Vuurden DG, Wesseling P, Vandertop WP, Noske DP, Wurdinger T, Kaspers GJL, Hulleman E, Wright K, Broniscer A, Bendel A, Bowers D, Crawford J, Fisher P, Hassall T, Armstrong G, Baker J, Qaddoumi I, Robinson G, Wetmore C, Klimo P, Boop F, Onar-Thomas A, Ellison D, Gajjar A, Cruz O, de Torres C, Sunol M, Rodriguez E, Alonso L, Parareda A, Cardesa T, Salvador H, Celis V, Guillen A, Garcia G, Muchart J, Trampal C, Martin ML, Rebollo M, Mora J, Piotrowski A, Kowalska A, Coyle P, Smith S, Rogers H, Macarthur D, Grundy R, Puccetti D, Salamat S, Kennedy T, Fangusaro J, Patel N, Bradley K, Casey K, Iskandar B, Nakano Y, Okada K, Osugi Y, Yamasaki K, Fujisaki H, Fukushima H, Inoue T, Matsusaka Y, Sakamoto H, Hara J, De Vleeschouwer S, Ardon H, Van Calenbergh F, Sciot R, Wilms G, Van Loon J, Goffin J, Van Gool S, Puccetti D, Salamat S, Rusinak D, Patel N, Bradley K, Casey K, Knight P, Onel K, Wargowski D, Stettner A, Iskandar B, Al-Ghafari A, Punjaruk W, Coyle B, Kerr I, Xipell E, Rodriguez M, Gonzalez-Huarriz M, Tunon MT, Zazpe I, Tejada-Solis S, Diez-Valle R, Fueyo J, Gomez-Manzano C, Alonso MM, Pastakia D, McCully C, Murphy R, Bacher J, Thomas M, Steffen-Smith E, Saleem K, Waldbridge S, Widemann B, Warren K, Miele E, Buttarelli F, Arcella A, Begalli F, Po A, Baldi C, Carissimo G, Antonelli M, Donofrio V, Morra I, Nozza P, Gulino A, Giangaspero F, Ferretti E, Elens I, De Vleeschouwer S, Pauwels F, Van Gool S, Fritzell S, Eberstal S, Sanden E, Visse E, Darabi A, Siesjo P, McDonald P, Wrogemann J, Krawitz S, Del Bigio M, Eisenstat D, Wolff J, Kwiecien R, Pietsch T, Faldum A, Kortmann RD, Warmuth-Metz M, Rutkowski S, Slavc I, Kramm CM, Uparkar U, Geyer R, Ermoian R, Ellenbogen R, Leary S, Triscott J, Hu K, Fotovati A, Yip S, Kast R, Toyota B, Dunn S, Hegde M, Corder A, Chow K, Mukherjee M, Ashoori A, Brawley V, Heslop H, Gottschalk S, Yvon E, Ahmed N, Wong TT, Yang FY, Lu M, Liang HF, Wang HE, Liu RS, Teng MC, Yen CC, Agnihotri S, Ternamian C, Jones C, Zadeh G, Rutka J, Hawkins C, Filipek I, Drogosiewicz M, Perek-Polnik M, Swieszkowska E, Baginska BD, Jurkiewicz E, Perek D, Kuehn A, Falkenstein F, Wolff J, Kwiecien R, Pietsch T, Gnekow A, Kramm C, Brooks MD, Jackson E, Piwnica-Worms D, Mitra RD, Rubin JB, Liu XY, Korshunov A, Schwartzentruber J, Jones DTW, Pfaff E, Sturm D, Fontebasso AM, Quang DAK, Albrecht S, Kool M, Dong Z, Siegel P, Von Diemling A, Faury D, Tabori U, Lichter P, Plass C, Majewski J, Pfister SM, Jabado N, Lulla R, Echevarria M, Alden T, DiPatri A, Tomita T, Goldman S, Fangusaro J, Qaddoumi I, Lin T, Merchant TE, Kocak M, Panandiker AP, Armstrong GT, Wetmore C, Gajjar A, Broniscer A, Gielen GH, Muehlen AZ, Kramm C, Pietsch T, Hubert C, Ding Y, Toledo C, Paddison P, Olson J, Nandhabalan M, Bjerke L, Bax D, Carvalho D, Bajrami I, Ashworth A, Lord C, Hargrave D, Reis R, Workman P, Jones C, Little S, Popov S, Jury A, Burford A, Doey L, Al-Sarraj S, Jurgensmeier J, Jones C, Carvalho D, Bjerke L, Bax D, Chen L, Kozarewa I, Baker S, Grundy R, Ashworth A, Lord C, Hargrave D, Reis R, Jones C, Bjerke L, Perryman L, Burford A, Bax D, Jury A, Popov S, Box G, Raynaud F, Hargrave D, Eccles S, Jones C, Viana-Pereira M, Pereira M, Burford A, Jury A, Popov S, Perryman L, Bax D, Forshew T, Tatevossian R, Sheer D, Pimental J, Pires M, Reis R, Jones C, Sarkar C, Jha P, Patrick IRP, Somasundaram K, Pathak P, Sharma MC, Suri V, Suri A, Gerges N, Haque T, Nantel A, Faury D, Jabado N, Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, Singhal A, Dunham C, Kerr J, Verreault M, Yip S, Wakimoto H, Jones C, Jayanthan A, Narendran A, Singh S, Dunn S, Giraud G, Holm S, Gustavsson B, Van Gool S, Kizyma R, Kizyma Z, Dvornyak L, Kotsay B, Epari S, Sharma P, Gurav M, Gupta T, Shetty P, Moiyadi A, Kane S, Jalali R. HIGH GRADE GLIOMAS. Neuro Oncol 2012; 14:i56-i68. [PMCID: PMC3483348 DOI: 10.1093/neuonc/nos102] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/27/2023] Open
|
31
|
Abstract
BACKGROUND Cognitive behaviour therapies (CBTs) have through several trials been demonstrated to reduce symptoms and disability in irritable bowel syndrome (IBS) patients, but the mechanisms responsible for the changes are still unknown. The aim of this study was to test a theoretical model of CBT and investigate if cognitions and/or behaviour mediated the changes seen in CBT for IBS. METHOD To assess for possible mediating effects, we applied path analysis to the dataset of 149 diagnosed participants randomized to mebeverine hydrochloride plus CBT or mebeverine hydrochloride alone. Primary outcome was symptom severity, while secondary outcomes were work and social adjustment and anxiety. RESULTS The path analyses supported mediational paths for all outcomes. Changes in behaviour and cognitions mediated all three outcomes, with models placing behaviour change 'upstream' of cognition change having best fit. The analyses of model fits revealed best fit for the anxiety model and hence provide increased confidence in the causal model of anxiety. CONCLUSIONS Changes in behaviour and cognitions mediate the change in CBT given to IBS patients. The results strengthen the validity of a theoretical model of CBT by confirming the interaction of cognitive, emotional and behavioural factors in IBS.
Collapse
Affiliation(s)
- S E Reme
- Department of Psychological Medicine, and Department of Primary Care, King's College Hospital, London.
| | | | | | | | | | | |
Collapse
|
32
|
Earis J, Deegan P, Stockton P, McKinnell S, Fewtrell R, Kennedy T. P75 Teaching emergency oxygen prescribing to medical students. Thorax 2011. [DOI: 10.1136/thoraxjnl-2011-201054c.75] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
33
|
Murray JC, Rainusso N, Roberts RA, Gomez AM, Egler R, Russell H, Okcu MF, Gururangan S, Fangusaro J, Young-Poussaint T, Lesh S, Onar A, Gilbertson R, Packer R, McLendon R, Friedman HS, Boyett J, Kun LE, Venkatramani R, Haley K, Gilles F, Sposto R, Ji L, Olshefski R, Garvin J, Tekautz T, Kennedy G, Rassekh R, Moore T, Gardner S, Allen J, Shore R, Moertel C, Atlas M, Lasky J, Finlay J, Valera ET, Brassesco MS, Scrideli CA, Oliveira RS, Machado HR, Tone LG, Finlay JL, Kreimer S, Dagri J, Grimm J, Bluml S, Britt B, Dhall G, Gilles F, Finlay JL, Brown RJ, Dhall G, Shah A, Kapoor N, Abdel-Azim H, Rao AAN, Wallace D, Boyett J, Gajjar A, Packer RJ, Pearlman ML, Sadighi Z, Bingham R, Vats T, Khatua S, Ko RH, O'Neil S, Lavey RS, Finlay JL, Dhall G, Davidson TB, Gilles F, Tovar J, Grimm J, Wong K, Olch A, Dhall G, Finlay JL, Murray JC, Honeycutt JH, Donahue DJ, Head HW, Alles AJ, Ray A, Pearlman M, Vats T, Khatua S, Baskin J, Qaddoumi I, Ahchu MS, Alabi SF, Arambu IC, Castellanos M, Gamboa Y, Martinez R, Montero M, Ocampo E, Howard SC, Finlay JL, Broniscer A, Baker SD, Baker JN, Panandiker AP, Onar-Thomas A, Chin TK, Merchant TE, Davidoff A, Kaste SC, Gajjar A, Stewart CF, Espinoza J, Haley K, Patel N, Dhall G, Gardner S, Jeffrey A, Torkildson J, Cornelius A, Rassekh R, Bedros A, Etzl M, Garvin J, Pradhan K, Corbett R, Sullivan M, McGowage G, Puccetti D, Stein D, Jasty R, Ji L, Sposto R, Finlay JL, Antony R, Gardner S, Patel M, Wong KE, Britt B, Dhall G, Grimm J, Krieger M, McComb G, Gilles F, Sposto R, Finlay JL, Davidson TB, Sanchez-Lara PA, Randolph LM, Krieger MD, Wu S, Panigrahy A, Shimada H, Erdreich-Epstein A, Puccetti DM, Patel N, Kennedy T, Salamat S, Bradfield Y, Park HJ, Yoon JH, Ahn HS, Shin HY, Kim SK, Im HJ, Ra YS, Won SC, Baek HJ, Sung KW, Hah JO, Lim YT, Lee GS, Lee YH, Kim HS, Park JK, Kim MK, Park JE, Chung NG, Choi HS, Campen CJ, Fisher PG, Ruge MI, Simon T, Suchorska B, Lehrke R, Hamisch C, Koerber F, Treuer H, Berthold F, Sturm V, Voges J, Davidson TB, Finlay JL, Dhall G, Kirsch M, Lindner C, Schackert G, Brown RJ, Krieger M, Dhall G, Finlay JL. PEDIATRICS CLINICAL RESEARCH. Neuro Oncol 2011. [DOI: 10.1093/neuonc/nor156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Tasdemiroglu E, Kaya M, Yildirim CH, Lucas KG, Bao L, Bruggeman R, Specht C, Murray JC, Donahue DJ, Galliani CA, Blondin NA, Hui P, Vortmeyer A, Hasbani J, Baehring J, Jensen RL, Lee J, Lake WB, Baskaya MK, Salamat MS, Kennedy T, Abraham S, Jensen RL, Lusis EA, Scheithauer B, Yachnis AT, Chicoine MR, Paulus W, Perry A, Chan DT, Kam MK, Ma BB, Ng SC, Siu DY, Ng HK, Poon WS, Dunbar EM, Dong HJ, Liu C, Chi YY, Keeling C, Yachnis AT, Stephen JH, Sievert AJ, Resnick AC, Storm PB, Judkins AR, Santi M, Kirsch M, Stelling A, Koch E, Salzer R, Schackert G, Steiner G, Pollo B, Maderna E, Valletta L, Guzzetti S, Eoli M, Calatozzolo C, Nunziata R, Salmaggi A, Finocchiaro G, Kastenhuber ER, Campos C, Brennan CW, Mellinghoff IK, Huse JT, Zhang H, Sergey M, Estrada DK, Kay AB, Wagner AS, Khanlou N, Vinters HV, Cloughesy TF, Yong WH. Pathology. Neuro Oncol 2010. [DOI: 10.1093/neuonc/noq116.s10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Bagust A, Boland A, Hockenhull J, Fleeman N, Greenhalgh J, Dundar Y, Proudlove C, Kennedy T, Moots R, Williamson P, Dickson R. Rituximab for the treatment of rheumatoid arthritis. Health Technol Assess 2010; 13 Suppl 2:23-9. [PMID: 19804686 DOI: 10.3310/hta13suppl2/04] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
This paper presents a summary of the evidence review group's critical review of the evidence for the clinical effectiveness and cost-effectiveness of rituximab for the treatment of severe rheumatoid arthritis (RA) following failure of previous therapy, including one or more tumour necrosis factor-alpha inhibitors (TNFi), compared with current standards of care, based upon the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The submission's clinical evidence came from one randomised, placebo-controlled, double-blind trial (REFLEX--Random Evaluation of Long-term Efficacy of Rituximab in Rheumatoid Arthritis) comparing rituximab plus methotrexate (MTX) with placebo plus MTX in 517 patients with long-standing refractory RA. Rituximab plus MTX was more effective than placebo plus MTX across a range of primary and secondary outcome measures, e.g. American College of Rheumatology (ACR) responses, Health Assessment Questionnaire (HAQ). However, this evidence cannot be used directly to address the manufacturer's analysis of the decision problem because, in the REFLEX trial, rituximab was not compared with a relevant comparator (e.g. leflunomide or second or third TNFi). Long-term efficacy data for retreatment with rituximab are favourable, with an estimated mean time to retreatment of 307 days (n = 164). Evidence from a further five trials is presented as the basis for indirect comparisons with other disease-modifying antirheumatic drugs (DMARDs); however, it is not clear that all relevant clinical studies have been included in the indirect comparison exercise, the rationale for the choice of indirect comparison method adopted is unclear and the indirect comparison method used to adjust the ACR responses only uses a single value for the reference placebo. The submitted microsimulation Markov model was based upon the REFLEX trial. For the 'NICE-recommended' scenario and the 'sequential TNFi' scenario, the original submission reports incremental cost-effectiveness ratios (ICERs) of 14,690 pounds and 11,601 pounds per quality-adjusted life-year (QALY) gained respectively. After model assumptions were adjusted to more realistic estimates by the ERG, the ICERs for the NICE-recommended scenario and the sequential use of TNFi range from 37,002 pounds to 80,198 pounds per QALY gained and from 28,553 pounds to 65,558 pounds per QALY gained respectively. The guidance issued by NICE in August 2007 states that rituximab in combination with methotrexate is recommended as an option for the treatment of adults with severe active rheumatoid arthritis who have had an inadequate response to or intolerance of other DMARDs including treatment with at least one TNFi therapy.
Collapse
Affiliation(s)
- A Bagust
- Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Bagust A, Boland A, Hockenhull J, Fleeman N, Greenhalgh J, Dundar Y, Proudlove C, Kennedy T, Moots R, Williamson P, Dickson R. Rituximab for the treatment of rheumatoid arthritis. Health Technol Assess 2009. [DOI: 10.3310/hta13suppl2-04] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
This paper presents a summary of the evidence review group’s critical review of the evidence for the clinical effectiveness and cost-effectiveness of rituximab for the treatment of severe rheumatoid arthritis (RA) following failure of previous therapy, including one or more tumour necrosis factor-α inhibitors (TNFi), compared with current standards of care, based upon the manufacturer’s submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The submission’s clinical evidence came from one randomised, placebo-controlled, double-blind trial (REFLEX – Random Evaluation of Long-term Efficacy of Rituximab in Rheumatoid Arthritis) comparing rituximab plus methotrexate (MTX) with placebo plus MTX in 517 patients with long-standing refractory RA. Rituximab plus MTX was more effective than placebo plus MTX across a range of primary and secondary outcome measures, e.g. American College of Rheumatology (ACR) responses, Health Assessment Questionnaire (HAQ). However, this evidence cannot be used directly to address the manufacturer’s analysis of the decision problem because, in the REFLEX trial, rituximab was not compared with a relevant comparator (e.g. leflunomide or second or third TNFi). Long-term efficacy data for retreatment with rituximab are favourable, with an estimated mean time to retreatment of 307 days (n = 164). Evidence from a further five trials is presented as the basis for indirect comparisons with other disease-modifying antirheumatic drugs (DMARDs); however, it is not clear that all relevant clinical studies have been included in the indirect comparison exercise, the rationale for the choice of indirect comparison method adopted is unclear and the indirect comparison method used to adjust the ACR responses only uses a single value for the reference placebo. The submitted microsimulation Markov model was based upon the REFLEX trial. For the ‘NICE-recommended’ scenario and the ‘sequential TNFi’ scenario, the original submission reports incremental cost-effectiveness ratios (ICERs) of £14,690 and £11,601 per quality-adjusted life-year (QALY) gained respectively. After model assumptions were adjusted to more realistic estimates by the ERG, the ICERs for the NICE-recommended scenario and the sequential use of TNFi range from £37,002 to £80,198 per QALY gained and from £28,553 to £65,558 per QALY gained respectively. The guidance issued by NICE in August 2007 states that rituximab in combination with methotrexate is recommended as an option for the treatment of adults with severe active rheumatoid arthritis who have had an inadequate response to or intolerance of other DMARDs including treatment with at least one TNFi therapy.
Collapse
Affiliation(s)
- A Bagust
- Liverpool Reviews and Implementation Group, UK
| | - A Boland
- Liverpool Reviews and Implementation Group, UK
| | | | - N Fleeman
- Liverpool Reviews and Implementation Group, UK
| | | | - Y Dundar
- Liverpool Reviews and Implementation Group, UK
| | - C Proudlove
- Liverpool Reviews and Implementation Group, UK
| | - T Kennedy
- Liverpool Reviews and Implementation Group, UK
| | - R Moots
- Liverpool Reviews and Implementation Group, UK
| | | | - R Dickson
- Liverpool Reviews and Implementation Group, UK
| |
Collapse
|
37
|
Ng T, Berz D, Birnbaum A, Dipetrillo TA, Henderson D, Kennedy T, Ready NE. Neoadjuvant carboplatin and weekly paclitaxel for stage Ib-IIIa non-small cell lung cancer (NSCLC): A Brown University Oncology Group (BrUOG) phase II study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.18502] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Birnbaum AE, Johnson TT, Rathore R, Khurshid H, Puthawala M, Radie Keane K, Ruhl C, Wanebo H, Kennedy T, Ready N. Induction cetuximab (C) followed by C, paclitaxel (P), carboplatin (CP) and concurrent radiation (RT) for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.16504] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
16504 Background: C is an IgG1 chimerized, monoclonal antibody that binds specifically to the epidermal growth factor receptor, which is expressed in 90–100% of HNC. We conducted a phase II study to evaluate the toxicity and efficacy of induction C followed by concurrent C with chemoRT for patients (pts) with SCCHN. Methods: Eligible pts had untreated stage III or IV, SCCHN. All pts received induction, single agent, C, 400 mg/m2 week 1, followed by 250 mg/m2 weeks 2, 3, and 4. Potentially operable pts then received C, 250 mg/m2, P 40 mg/m2 and CP AUC=1, weekly x 5 wks, with 45 Gy RT then underwent endoscopic biopsy. If the biopsy was negative, pts received 3 additional weekly doses of C, P, CP and 22–27 Gy boost RT. Inoperable pts received 8 weeks of C, P and CP and 66.6–72 Gy RT. All pts then received maintenance C 250 mg/m2/week x 24 weeks. Results: 29 pts have been enrolled. Male:Female 18:11. Median age = 55 (38–75). Primary sites included oral cavity (10 pts), oropharynx (1), larynx (12), hypopharynx (2), and glottis (4). The tumor stages were III (10 pts), IV (19). Toxicity data are available for 23 pts. 2 of 23 (9%) had grade (G) 4 toxicities (hypokalemia =1, ischemic colitis=1) however there were no treatment related deaths. G 2 toxicities included rash (52%), dysphagia (35%), mucositis (43.5%) and hypomagnesemia (9%). G 3 toxicities included rash (9%), dysphagia (44%), mucositis (26%) and XRT dermatitis (18%). Induction C responses by RECIST criteria were SD (14 pts) 61%, PR (7) 30%, and CR (1) 4%. Conclusion: C can be safely administered with chemoRT (CRT) for pts with HNC. C increases cutaneous toxicity but does not increase in-field CRT side effects. There were no unexpected high-grade adverse events. Preliminary single agent activity of C in untreated SCCHN is promising. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. E. Birnbaum
- Brown University, Providence, RI; Roger Williams Medical Center, Providence, RI; Memorial Hospital Rhode Island, Pawtucket, RI; Rhode Island Hospital, Providence, RI; North Main Radiation Oncolgy, Providence, RI; Brown University Oncology Group, Providence, RI; BrUOG; Duke University, Durham, NC
| | - T. T. Johnson
- Brown University, Providence, RI; Roger Williams Medical Center, Providence, RI; Memorial Hospital Rhode Island, Pawtucket, RI; Rhode Island Hospital, Providence, RI; North Main Radiation Oncolgy, Providence, RI; Brown University Oncology Group, Providence, RI; BrUOG; Duke University, Durham, NC
| | - R. Rathore
- Brown University, Providence, RI; Roger Williams Medical Center, Providence, RI; Memorial Hospital Rhode Island, Pawtucket, RI; Rhode Island Hospital, Providence, RI; North Main Radiation Oncolgy, Providence, RI; Brown University Oncology Group, Providence, RI; BrUOG; Duke University, Durham, NC
| | - H. Khurshid
- Brown University, Providence, RI; Roger Williams Medical Center, Providence, RI; Memorial Hospital Rhode Island, Pawtucket, RI; Rhode Island Hospital, Providence, RI; North Main Radiation Oncolgy, Providence, RI; Brown University Oncology Group, Providence, RI; BrUOG; Duke University, Durham, NC
| | - M. Puthawala
- Brown University, Providence, RI; Roger Williams Medical Center, Providence, RI; Memorial Hospital Rhode Island, Pawtucket, RI; Rhode Island Hospital, Providence, RI; North Main Radiation Oncolgy, Providence, RI; Brown University Oncology Group, Providence, RI; BrUOG; Duke University, Durham, NC
| | - K. Radie Keane
- Brown University, Providence, RI; Roger Williams Medical Center, Providence, RI; Memorial Hospital Rhode Island, Pawtucket, RI; Rhode Island Hospital, Providence, RI; North Main Radiation Oncolgy, Providence, RI; Brown University Oncology Group, Providence, RI; BrUOG; Duke University, Durham, NC
| | - C. Ruhl
- Brown University, Providence, RI; Roger Williams Medical Center, Providence, RI; Memorial Hospital Rhode Island, Pawtucket, RI; Rhode Island Hospital, Providence, RI; North Main Radiation Oncolgy, Providence, RI; Brown University Oncology Group, Providence, RI; BrUOG; Duke University, Durham, NC
| | - H. Wanebo
- Brown University, Providence, RI; Roger Williams Medical Center, Providence, RI; Memorial Hospital Rhode Island, Pawtucket, RI; Rhode Island Hospital, Providence, RI; North Main Radiation Oncolgy, Providence, RI; Brown University Oncology Group, Providence, RI; BrUOG; Duke University, Durham, NC
| | - T. Kennedy
- Brown University, Providence, RI; Roger Williams Medical Center, Providence, RI; Memorial Hospital Rhode Island, Pawtucket, RI; Rhode Island Hospital, Providence, RI; North Main Radiation Oncolgy, Providence, RI; Brown University Oncology Group, Providence, RI; BrUOG; Duke University, Durham, NC
| | - N. Ready
- Brown University, Providence, RI; Roger Williams Medical Center, Providence, RI; Memorial Hospital Rhode Island, Pawtucket, RI; Rhode Island Hospital, Providence, RI; North Main Radiation Oncolgy, Providence, RI; Brown University Oncology Group, Providence, RI; BrUOG; Duke University, Durham, NC
| |
Collapse
|
39
|
Boud DJ, Dunn J, Kennedy T, Thorley R. The Aims of Science Laboratory Courses: a Survey of Students, Graduates and Practising Scientists. ACTA ACUST UNITED AC 2007. [DOI: 10.1080/0140528800020408] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
40
|
Chakravarty K, McDonald H, Pullar T, Taggart A, Chalmers R, Oliver S, Mooney J, Somerville M, Bosworth A, Kennedy T. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) 2006; 47:924-5. [PMID: 16940305 DOI: 10.1093/rheumatology/kel216a] [Citation(s) in RCA: 105] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Affiliation(s)
- K Chakravarty
- Harold Wood Hospital, BHR NHS Trust, Romford, Essex RM7 OBE, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Sharma P, Kimler BF, Kennedy T, Smith EJ, Khan QJ, Fabian CJ. Correlation of statin use with breast random periareolar fine needle aspiration (RPFNA) cytomorphology in high risk postmenopausal women. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.1031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1031 Background: In vitro studies have demonstrated that statins (HMG CoA reductase inhibitors) suppress tumor growth and proliferation in breast cancer cell lines. Published clinical data on the chemoprotective role of statins in breast cancer are conflicting. Moreover, there are no published studies specifically examining the impact of statin use on breast cancer risk biomarkers in high risk women. We have previously demonstrated that cytologic atypia detected by RPFNA is associated with a 5 fold increase in short term risk of breast cancer in high risk women. The aim of this study was to explore the effect of statin use on breast RPFNA cytomorphology in postmenopausal women at high risk of developing breast cancer (based on personal and family history). Methods: Thehigh risk breast clinic database at the University of Kansas Medical Center was queried from April 2002 to September 2005 for statin use in postmenopausal women. We first identified postmenopausal women who underwent RPFNA while on a statin (cases). Postmenopausal women who underwent RPFNA while not on a statin (controls) were then identified and matched with statin users for known breast cancer risk factors (age, 5 year Gail risk and BMI). Frequencies of categorical variables were assessed using chi-square analysis. Continuous variables were assessed using Mann-Whitney non parametric test. Results: 504 postmenopausal women were identified. Thirty five of these 504 women underwent RPFNA while on statin therapy. For statin users (cases), the median age was 56 years, median 5 year Gail risk was 3.6%, median BMI was 28 and the median duration of statin use was 1.4 years (range 0.3 to 13 yrs). Sixty nine controls were identified. There was no difference between cases and controls with respect to HRT use (54% vs 40%, p=0.22), duration of HRT use (p=0.30) and visual breast density (p=0.80). RPFNA atypia was detected in 11% of cases and 26% of controls (p=0.13). Conclusion: Although prevalence of RPFNA atypia was less frequent among statin users, this difference was not statistically significant in this small cohort of high risk women with relatively short duration of statin use. Larger studies are warranted to investigate this further. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Sharma
- University of Kansas Medical Center, Kansas City, KS
| | - B. F. Kimler
- University of Kansas Medical Center, Kansas City, KS
| | - T. Kennedy
- University of Kansas Medical Center, Kansas City, KS
| | - E. J. Smith
- University of Kansas Medical Center, Kansas City, KS
| | - Q. J. Khan
- University of Kansas Medical Center, Kansas City, KS
| | - C. J. Fabian
- University of Kansas Medical Center, Kansas City, KS
| |
Collapse
|
42
|
Suntharalingam M, Dipetrillo T, Akerman P, Wanebo H, Daly B, Doyle LA, Krasna MJ, Kennedy T, Safran H. Cetuximab, paclitaxel, carboplatin and radiation for esophageal and gastric cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4029] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4029 Background: Cetuximab is an IgG1, chimerized, monoclonal antibody that binds specifically to the epidermal growth factor receptor. Cetuximab improves survival when combined with radiation for patients with locally advanced head and neck cancer. We evaluated the safety and efficacy of the addition of cetuximab to concurrent chemoradiation for patients with esophageal and gastric cancer. Methods: Patients with adenocarcinoma or squamous cell cancer of the esophagus or stomach without distant organ metastases were eligible. Patients with locally advanced disease from mediastinal, celiac, portal and gastric lymphadenopathy were eligible. Surgical resection was not required. Clinical complete response was defined as no tumor on postreatment endoscopic biopsy. Patients received cetuximab, 400mg/m2 week #1 then 250 mg/m2/week for 5 weeks, paclitaxel, 50 mg/m2/week, and carboplatin, AUC =2 weekly for 6 weeks, with concurrent 50.4 Gy radiation. Results: Thirty-seven patients have been entered. The median age was 61 (range of 30–87). Thirty-four have esophageal cancer and 3 have gastric cancer. Of the patients with esophageal cancer, twenty-five have adenocarcinoma and nine have squamous cell cancer. Thus far, 30 patients have completed treatment and are evaluable for toxicity. There have been no grade 4 non-hematologic toxicities and 1 pt had grade 4 neutropenia (3%). Six patients (20%) had grade 3 esophagitis. Other grade 3 toxicities included dehydration (n=5), rash (n=9), and paclitaxel/cetuximab hypersensitivity reactions (n=2). Eighteen of 27 patients (67%) have had clinical complete response. Seven pts out of 16 (43%) who have gone to surgery have had a pathologic CR. Conclusions: Cetuximab can be safely administered with chemoradiation for patients with esophageal cancer. Consistent with the data in head and neck cancer, cetuximab increases cutaneous toxicity but does not increase mucositis/esophagitis when combined with chemoradiation. Further evaluation is ongoing. [Table: see text]
Collapse
Affiliation(s)
- M. Suntharalingam
- University of Maryland School of Medicine, Baltimore, MD; Brown University Oncology Group, Providence, RI
| | - T. Dipetrillo
- University of Maryland School of Medicine, Baltimore, MD; Brown University Oncology Group, Providence, RI
| | - P. Akerman
- University of Maryland School of Medicine, Baltimore, MD; Brown University Oncology Group, Providence, RI
| | - H. Wanebo
- University of Maryland School of Medicine, Baltimore, MD; Brown University Oncology Group, Providence, RI
| | - B. Daly
- University of Maryland School of Medicine, Baltimore, MD; Brown University Oncology Group, Providence, RI
| | - L. A. Doyle
- University of Maryland School of Medicine, Baltimore, MD; Brown University Oncology Group, Providence, RI
| | - M. J. Krasna
- University of Maryland School of Medicine, Baltimore, MD; Brown University Oncology Group, Providence, RI
| | - T. Kennedy
- University of Maryland School of Medicine, Baltimore, MD; Brown University Oncology Group, Providence, RI
| | - H. Safran
- University of Maryland School of Medicine, Baltimore, MD; Brown University Oncology Group, Providence, RI
| |
Collapse
|
43
|
Kennedy T. A colour atlas of upper gastrointestinal surgery. Charles Grant Clark. 310 mm × 260 mm. Pp. 168. Illustrated in black and white and colour. 1983. London: Wolfe. £50.00. Br J Surg 2005. [DOI: 10.1002/bjs.1800700827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
44
|
Kennedy T. The management of trauma. Edited G. D. Zuidema, R. B. Rutherford and W. F. Ballinger II. Third edition; 278 × 190 mm. Pp. 849 + xiv. Illustrated. 1979. Eastbourne: Saunders. £25·75. Br J Surg 2005. [DOI: 10.1002/bjs.1800670828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
45
|
Kennedy T. Operating Theatre Technique. R. J. Brigden. 250 × 196 mm. Pp. 811 + xii. Illustrated. 1980. Edinburgh: Churchill Livingstone. £35·00. Br J Surg 2005. [DOI: 10.1002/bjs.1800680231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
46
|
Kennedy T. Topics in gastroenterology. 10. Edited by D. P. Jewell and W. S. Selby. 240 mm × 160 mm. Pp. 337 + x. Illustrated. 1982. Oxford: Blackwell Scientific. £20.00. Br J Surg 2005. [DOI: 10.1002/bjs.1800700833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
47
|
Kennedy T. Early gastric cancer. Proceedings of the second BSG. SK & F. International Workshop 1981. Dr P. B. Cotton. 235 × 160 mm. Pp. 83. Illustrated. 1982. Welwyn Garden City: Smith Kline & French. Free. Br J Surg 2005. [DOI: 10.1002/bjs.1800700431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
48
|
Miller Y, Keith R, Hirsch F, Dempsey E, Franklin W, Kennedy T. P-265 Natural history of untreated endobronchial carcinoma in situ. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80759-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
49
|
Miller Y, Hyun D, Blatchford P, Lewis M, Keith R, Kennedy T, Franklin W, Kittelson J, Hirsch F. P-264 Ki67 proliferation index in endobronchial biopsies: Associationwith lung cancer, airflow obstruction and smoking history. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80758-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
50
|
Franklin W, Sugita M, Haney J, Miller Y, Keith R, Mitchell J, Hirsch F, Kennedy T, Bemis L. P-245 245 Detection of RNA biomarkers in sputum of lung cancer patientsand high risk smokers. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80739-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|